IL-7

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

Retrieved on: 
Tuesday, April 2, 2024
Mallinckrodt, Inflammation, Pharmacology, McGill University, Organization, Acute radiation syndrome, ARS, KOSDAQ, Research, EDT, Senior, Doctor of Philosophy, IL-7, Human Genome Sciences, Drug development, Division, NIT, Vertex Pharmaceuticals

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).

Key Points: 
  • ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).
  • Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc.
  • In his new role, Dr. Oh will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea.
  • Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech."

OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook

Retrieved on: 
Friday, January 19, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Journal of Immunology, HCC, ICI, CD47, Cancer, EMA, Journal, Pembrolizumab, IL-7, Kidney transplantation, Acute lymphoblastic leukemia, Annals of Oncology, Nivolumab, Fortification, ESMO, Hepatocellular carcinoma, Safety, Inflammation, Ulcerative colitis, Patent, Ovarian cancer, Failure, Survival, Immunotherapy, Boehringer Ingelheim, Committee, Myelocyte, Oncology, Patient, European Medicines Agency, ALL, Partnership, Lung cancer, Head, Pancreatic cancer, Phase II, FDA, Clinical trial, FOLFIRI, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.
  • Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “The Company has a broad portfolio of 5 products in clinical development with significant advances reached in 2023 and key milestones expected in 2024.
  • Our shared ambition at OSE is to create value by leading our two advanced assets in phase 2 and phase 3 to a clinical inflection point allowing a structuring agreement.
  • Thus, from Q1 2024, the Company could have validated doses and therapeutic regimens to consider the implementation of possible other clinical trials.

NeoImmuneTech Welcomes a New President for its Development and Business

Retrieved on: 
Monday, January 15, 2024
Senior, Research, Human Genome Sciences, Biosimilar, NIT, Pharmacology, McGill University, Division, Drug development, Inflammation, Acute radiation syndrome, Organization, Doctor of Philosophy, IL-7, ARS, Mallinckrodt, Vertex Pharmaceuticals, Pharmaceutical industry

ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

Key Points: 
  • ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.
  • Dr. Oh is an expert in regulatory policies and drug development, encompassing both biologics and small molecules.
  • Se Hwan Yang, Ph.D., Chief Executive Officer of NeoImmuneTech, Inc. said: "We are delighted to welcome Dr. Oh to our team.
  • His strong expertise and extensive network are invaluable assets that will propel our clinical development program and business activities.

Q32 Bio and Homology Medicines Announce Merger Agreement

Retrieved on: 
Thursday, November 16, 2023
Bristol Myers Squibb, ANCA, AA, Clinical trial, Patient, Alopecia areata, Atopic dermatitis, Therapy, Q32, OrbiMed, Trial of the century, TSLP, IL-7, System, Autoimmunity, AAV, OUP, Vaccine, Pharmaceutical industry

WALTHAM, Mass. and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.

Key Points: 
  • and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
  • The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases.
  • Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.
  • “The proposed merger with Homology Medicines and concurrent private placement is expected to provide Q32 Bio with the capital to drive development of our autoimmune and inflammatory pipeline through multiple clinical milestones,” said Jodie Morrison, Chief Executive Officer of Q32 Bio.

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Retrieved on: 
Monday, December 4, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Rheumatism, IL-7, Congress, WAC, Inflammation, World Allergy Organization, Abstract, Biology, Research fellow, TSLP, Vaccine, Forestry

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.
  • “Introducing Zura Bio’s ZB-168 and ZB-880 at World Allergy Congress is an opportunity to share the unique science behind these assets.
  • ZB-168 uniquely inhibits both IL-7 and TSLP, while ZB-880 prevents IL-33 mediated-activation of ST2-dependent and independent inflammation.
  • “We believe these could have applicability in the dermatological, rheumatological, gastrointestinal and respiratory spaces, and we are very excited about taking these development programs forward.”

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Contract research organization, Business analyst, Scleroderma, Benaroya Research Institute, Clinical trial, Administration, Research and development, Inflammation, Strategic planning, Interleukin 7, Alopecia areata, Research fellow, G&A, Ulcerative colitis, Thymic stromal lymphopoietin, Atopic dermatitis, TSLP, R, CMC, Chronic obstructive pulmonary disease, IL-7, Hidradenitis suppurativa, Asthma, Allergy, Pharmaceutical industry, Cryptocurrency

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.
  • "In the third quarter, Zura Bio made significant progress in its strategic planning across various key areas, including Clinical, Regulatory, CMC, and Translational Science.
  • This progress positions Zura Bio for clinical trial readiness in 2024," stated Dr. Someit Sidhu, Chief Executive Officer of Zura Bio.
  • Zura Bio anticipates that its cash and cash equivalents are sufficient to fund its planned operations into 2026.

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

Retrieved on: 
Wednesday, September 13, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Depression, Lupus erythematosus, Therapy, IL-7, Hair loss, Bio, Anxiety, TSLP, Pathology, Quality of life, Woman, Atopic dermatitis, Alopecia areata, Incidence, Hair, Patient, Immune system, Disease, Autoimmunity, Inflammation, Pharmaceutical industry

Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.

Key Points: 
  • Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.
  • Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
  • Thompson, Ph.D., executive vice president, research and development, Horizon.
  • Bempikibart has the potential to provide long-term, durable improvement in hair loss, including the potential for disease remittance,” added Jason Campagna, M.D., Ph.D., chief medical officer, Q32 Bio.

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Retrieved on: 
Tuesday, September 12, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Maintenance, BRI, Asthma, IL-7, Research fellow, TSLP, Doctor of Philosophy, DSM-IV codes, Inflammation, Benaroya Research Institute, Interleukin 7, Cytokine, Vaccine

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and Benaroya Research Institute (BRI), a Seattle based non-profit research institute within Virginia Mason Franciscan Health, announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha (IL-7Rα) in Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) signaling pathways.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and Benaroya Research Institute (BRI), a Seattle based non-profit research institute within Virginia Mason Franciscan Health, announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha (IL-7Rα) in Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) signaling pathways.
  • Zura Bio is currently advancing ZB-168, a monoclonal antibody targeting IL-7Rα, for the treatment of immune and inflammatory disorders.
  • At Benaroya Research Institute, this collaboration will leverage the expertise of Dr. Steve Ziegler, a world-renown authority in TSLP and IL-7 biology.
  • "We are thrilled to partner with the Benaroya Research Institute as we further explore the role of IL-7Rα in immune-mediated disorders," said Michael Howell, PhD, Chief Scientific Officer and Head of Translational Science at Zura Bio.

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, August 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Inflammation, Asthma, IL-7, Research fellow, TSLP, G&A, Atopic dermatitis, Guggenheim, Scleroderma, Ulcerative colitis, Research and development, Chronic obstructive pulmonary disease, Acquisition, Russell, Hidradenitis suppurativa, Administration, Eli Lilly and Company, R, Press release, BAFF, Conference, Pharmaceutical industry, Cryptocurrency

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights.
  • Research and Development (R&D) expenses: R&D expenses were $28.2 million for the second quarter ended June 30, 2023, compared to $0.1 million for the second quarter ended June 30, 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $5.7 million for the second quarter ended June 30, 2023, compared to $0.8 million for the second quarter ended June 30, 2022.
  • Members of the Zura Bio team will participate in the following upcoming conferences in the second half of 2023:
    Stifel 2023 Immunology and Inflammation Virtual Summit: September 10 - 20, 2023
    Guggenheim Securities 5th Annual Inflammation & Immunology Conference: November 6 - 7, 2023